Skip to main content

Table 2 Cohort demographics—blood samples

From: Alzheimer’s disease-associated (hydroxy)methylomic changes in the brain and blood

 

Controls

Converters

Baseline (T1)

N

42

54

 Gender (m/f)

10/32

17/34

 Age at baseline (mean ± SD)

81.00 ± 3.11

82.31 ± 3.55

 APOE4 carriers

43%

43%

Follow-up (T2)

N

42

41

 Gender (m/f)

10/32

13/28

 Age at baseline (mean ± SD)

81.00 ± 3.11

82.01 ± 3.51

 APOE4 carriers

43%

41%

  1. Blood samples were obtained from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe) cohort, and HM 450K array BS data was generated. The cohort includes controls, who showed no signs at baseline or follow-up, and converters who showed no signs of dementia at baseline, but were diagnosed with AD dementia at follow-up. DNA samples were collected at baseline and follow-up for both groups. Displayed is the number of samples in each group, the distributions of Gender and Age at baseline, and the percentage of APOE ɛ4 allele carriers